Agios slips on updated Phase I hematology data

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shed $12.46 (10%) to $110.13 on Friday after updated Phase I data for AG-221 and AG-120 showed lower response rates in patients with advanced hematological malignancies than interim data reported in November. The results were presented at the European Hematology Association meeting in Vienna.

AG-221, an inhibitor of mutated isocitrate dehydrogenase 2 ( IDH2), led to a 40% overall response rate and 16% complete response rate in 158 evaluable patients; 76% of responses lasted at least six months. In November, data from 45 evaluable patients showed AG-221 led to a 56% ORR and 13% CR. The trial included patients with advanced hematologic malignancies, including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), who have an IDH2 mutation. ...